Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations Chukwunonso K. Nwabufo Review Article 18 August 2023 Pages: 89 - 105
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach Liangang ChenNa YaoKai Zhang Original Article 14 October 2023 Pages: 107 - 119
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer Yao LiangOsamu MaedaYuichi Ando Original Article 28 October 2023 Pages: 121 - 127
Are novel oral oncolytics underdosed in obese patients? Lishi LinEllen K. O. van der MeerAlwin D. R. Huitema Original Article Open access 31 October 2023 Pages: 129 - 136
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Yukio TonozukaHiroshi TanakaYoshihide Kakimoto Original Article Open access 03 November 2023 Pages: 137 - 149
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer Xinyu WangShujun GuXu Qi Original Article 05 November 2023 Pages: 151 - 159
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure Hirotaka ImamakiMitsuaki OuraYoshinao Ozaki Short Communication Open access 22 August 2023 Pages: 161 - 167
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection Cléa TardyAlicja PuszkielAudrey Thomas Schoemann Short Communication 24 August 2023 Pages: 169 - 175